top of page

Novo Nordisk’s Parent Company to Acquire CMO Giant Catalent for $16.5bn 

In a significant move within the pharmaceutical industry, Novo Holdings, the parent company of Danish drugmaker Novo Nordisk, has announced its definitive agreement to acquire Catalent for $16.5 billion in an all-cash deal. This strategic acquisition underscores Novo Nordisk's commitment to enhancing its supply chain capabilities and meeting the surging demand for its leading diabetes and anti-obesity drugs, Ozempic and Wegovy.

The deal, valued at $63.50 per share in cash, represents a premium of 16.5% to Catalent's closing price on February 2, 2024. Novo Nordisk's shares saw a 3.63% rise in Copenhagen, reflecting investor confidence in the acquisition's potential benefits. Similarly, Catalent's shares surged by as much as 10% to a nine-month high in New York, signalling market approval of the agreement.

One of the primary drivers behind this acquisition is to gain greater control over the supply chain, particularly in addressing manufacturing quality issues that have previously affected Novo Nordisk. Catalent, already a key supplier for Novo’s "fill and finish" work, will now exclusively produce Novo Nordisk drugs, eliminating past challenges related to manufacturing quality and regulatory compliance.

From a technical standpoint, Novo Holdings will acquire three manufacturing sites from Catalent, located in Italy, Belgium, and the United States. These sites will play a pivotal role in expanding production capacity for Novo Nordisk's weight loss drugs, notably Ozempic and Wegovy, which have experienced exceptional demand but faced supply constraints. Financially, the acquisition is poised to bolster Novo Nordisk's position in the rapidly growing obesity drug market, projected to reach $100 billion by the end of the decade. The surge in demand for these drugs, endorsed by influential figures like Elon Musk and Oprah Winfrey, has propelled Novo Nordisk's valuation beyond $500 billion, solidifying its status as Europe's most valuable company. In addition, as Novo Nordisk faces competition from rivals like Eli Lilly, this acquisition positions the company strategically to maintain its competitive edge and solidify its leadership in the pharmaceutical landscape.

Despite concerns raised by the European Union's drugs regulator regarding potential risks to medicine availability, Novo Nordisk's acquisition is not expected to trigger antitrust issues in the US, given the drugmaker is only buying three out of 50 sites. Upon closing, Catalent will transition into a private company, with its shares no longer trading on the New York Stock Exchange. In navigating this complex deal, both Catalent and Novo Nordisk have enlisted top-tier financial and legal advisors. Citi and J.P. Morgan are acting as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor to Catalent, and Jones Day is serving as legal advisor to the Catalent Board of Directors. Morgan Stanley is acting as financial advisor to Novo Holdings, and Goodwin Procter LLP is serving as legal advisor to Novo Holdings.

In conclusion, Novo Holdings' acquisition of Catalent marks a pivotal moment for both companies, poised to unlock synergies, strengthen supply chain resilience, and capitalize on the booming demand for weight loss drugs. As Novo Nordisk continues its trajectory of growth and innovation, this strategic move reaffirms its commitment to driving positive health outcomes worldwide.

Written by: Mehak Mahajan

Sources:  Reuters, Economic Times, Bloomberg, Fierce Pharma, Mergerlinks

Recent Posts

See All

ChapStick Brand Acquired by Suave Brands Company

On 25th January 2024, Suave Brands Company announced their acquisition of Chapstick for approximately $510 million. Suave Brands Company is currently a portfolio company of Yellow Wood Partners, with


bottom of page